Diabetes has quietly become one of the most consequential public health challenges of our time. Beyond its well-documented impact on the heart, kidneys, and metabolism, the disease carries a less visible but equally devastating consequence: progressive vision loss. Across the Middle East and globally, diabetic eye disease remains a leading cause of preventable blindness, driven by rising diabetes prevalence, delayed diagnosis, and limited access to advanced surgical care.

For ophthalmologists, the clinical reality is clear. More diabetic patients are presenting with complex retinal complications that require highly precise, time-sensitive surgical intervention. As patient volumes increase and surgical demand outpaces the supply of trained specialists, efficiency, safety, and outcomes are no longer optional. They are essential.

It is against this backdrop that Alcon introduced UNITY VCS, its next-generation combined cataract and vitreoretinal surgical platform, during the Evolving Practice of Ophthalmology Middle East Conference (EPOMEC) 2025 in Dubai. The launch was not positioned as a routine product unveiling, but as a response to a mounting regional and global clinical need.

A strategic presence at EPOMEC

EPOMEC has steadily evolved into one of the most influential ophthalmology gatherings in the region, drawing specialists from the UAE, GCC countries, and increasingly from North Africa. For Alcon, participation in the conference reflects more than market presence.

“EPOMEC is a very important congress in this part of the world,” said Rajkumar Narayanan, SVP and President, International at Alcon. “It brings together leading surgeons and professionals not just from the UAE or the GCC, but from a much broader geography. The scope of this meeting is large, and the quality of scientific and educational content is very high.”

Narayanan emphasized that Alcon’s alignment with EPOMEC stems from shared priorities. “As a company that prioritizes science, data, education, and training, this meeting is a natural fit for us. There is a close symbiosis between the objectives of EPOMEC and how we want to show up as Alcon.”

That alignment was highlighted by Dr. Saleh Saif Al Messabi, President of EPOMEC 2025, who described the conference as a platform designed to bring world-class ophthalmic science and technology closer to regional practitioners.

“Our goal is to create one strong platform where, if you attend this meeting, you feel it is enough for the year. You see the science, the technology, and the people all in one place.” Dr. Al Messabi noted.

Long-term commitment

Alcon’s approach to innovation is grounded in sustained investment. According to Narayanan, the company reinvests approximately 10 percent of its global revenue into research and development.

“At any point in time, we have about 100 projects ongoing,” he said. “This year alone, we are launching eight to ten new products globally. UNITY VCS is one of them, and it represents a transformative change in how cataract and vitreoretinal surgeries can be performed.”

That level of R&D investment has not gone unnoticed by clinicians. Reflecting on the pace of technological evolution, Dr. Al Messabi remarked, “To see a company spending 10 percent of its revenue on R&D is almost unheard of in our field. But it proves itself in the quality we see. Every platform feels like the best, until the next one comes and surpasses it.”

Precision surgery, enhanced efficiency

Diabetes-related retinal disease remains one of the most complex surgical challenges in ophthalmology. Patients often require vitreoretinal procedures to manage complications such as diabetic retinopathy, macular edema, or vitreous hemorrhage. These surgeries demand extreme precision, minimal intraocular trauma, and efficient execution.

As UNITY VCS enters the Middle East market, both industry and clinicians see strong alignment between technology capability and regional expertise.

UNITY VCS was designed to meet these demands by combining cataract and vitreoretinal capabilities within a single platform.

“The system allows surgeons to perform cataract surgery and vitreoretinal surgery on the same equipment,” Narayanan explained. “This is especially relevant for diabetic patients, who often develop retinal complications requiring surgical intervention.”

Beyond versatility, the system introduces technical advancements aimed at reducing surgical time and intraocular stress. “This is not a small step forward,” he said. “with more than a dozen first-to-market innovations and safety features, UNITY VCS provides superior efficiency for cataract and vitreoretinal surgery, compared to our previous best-in-class technologies, and without compromising safety

Among its key features is a 30,000-speed vitreous cutter, enabling faster vitreous removal, and a multi-spot laser system, replacing traditional single-spot lasers.

“For the first time, Alcon is introducing a multi-spot laser,” Narayanan noted. “Instead of applying one laser spot at a time, surgeons can deliver multiple spots in a single pulse. That means faster treatment with greater precision.”

The platform also addresses a long-standing challenge in probe design. Surgeons had previously highlighted the trade-off between smaller incisions and probe stability. UNITY VCS introduces a 27-gauge probe with the stiffness of a 25-gauge, balancing minimal invasiveness with surgical control.

“These refinements allow surgeons to work faster and with less energy inside the eye,” Narayanan said. “Less energy means less trauma, which directly benefits the patient.”

Training, data, and responsible adoption

Alcon’s strategy does not stop at technology deployment. Recognizing that advanced systems require equally advanced training, the company has expanded its global network of Alcon Experience Centers, including a newly opened regional educational training facility in Jeddah.

“We invite surgeons to test our equipment, train on artificial and animal eyes, and understand how different settings impact outcomes,” Narayanan said. “It’s about ensuring surgeons are confident before they ever use the technology on a patient.”

He likened the process to performance training. “If someone puts a Ferrari in front of me and I don’t know how to drive it, it’s another car. Training is what unlocks the value of the technology.”

Data generation is another critical pillar. Alcon conducts clinical studies to quantify efficiency gains, safety improvements, and outcome consistency. “We don’t just claim efficiency,” Narayanan said. “We generate data to demonstrate it. Patient safety is non-negotiable.”

A platform with regional relevance

As UNITY VCS enters the Middle East market, both industry and clinicians see strong alignment between technology capability and regional expertise.

“This part of the world has very qualified surgeons,” Narayanan observed. “Introducing a sophisticated platform here makes sense because there are skilled professionals ready to use it to its full potential.”

For Dr. Saleh, the technology represents more than equipment. “This platform will be in operating rooms for the next eight to ten years,” he said. “Adopting the best technology is not promotion. It is a natural decision when it improves how we care for patients.”

UNITY VCS is more than just a technological advancement in an area where diabetes is becoming more common and can have a catastrophic effect on vision. It represents a comprehensive strategy that combines ultramodern innovation, demanding surgeon training, and unrelenting clinical accountability. It helps protect one of humanity’s most valuable senses, sight, by enabling ophthalmologists to provide safer, quicker, and more accurate care.

Click here to join our WhatsApp channel here

Disclaimer: Please refer to relevant products DFU’s or operators manuals for complete list of indications, contraindications and warnings

References
1: Irannejad A, Tambat S, Abulon DJK. Retropulsion and Mass flow of 27-gauge Vitrectomy Probes: Comparison of Dual-blade/flat-tipped probes and single-blade/beveled probes. 2021. Poster presentation.
2. Alcon Data on File, 2024. [REF-24379]
3 Urgent action needed as global diabetes cases increase four-fold over past decades
4 WHO EMRO – Eyes on diabetes